AstraZeneca plc (LON:AZN)‘s stock had its “neutral” rating reissued by equities researchers at JPMorgan Chase & Co. in a research note issued to investors on Monday. They currently have a GBX 4,900 ($63.96) price target on the biopharmaceutical company’s stock. JPMorgan Chase & Co.’s price objective would suggest a potential downside of 1.81% from the company’s previous close.

A number of other research firms have also recently issued reports on AZN. Shore Capital reiterated a “hold” rating on shares of AstraZeneca plc in a report on Thursday, June 23rd. Credit Suisse Group AG reiterated an “underperform” rating and issued a GBX 4,000 ($52.21) price objective on shares of AstraZeneca plc in a report on Wednesday, July 13th. Citigroup Inc. reiterated a “buy” rating on shares of AstraZeneca plc in a report on Friday, September 23rd. Goldman Sachs Group Inc. set a GBX 4,000 ($52.21) price objective on AstraZeneca plc and gave the stock a “sell” rating in a report on Wednesday, June 29th. Finally, Jefferies Group increased their target price on AstraZeneca plc from GBX 4,800 ($62.66) to GBX 5,050 ($65.92) and gave the company a “hold” rating in a report on Thursday, August 4th. Five research analysts have rated the stock with a sell rating, fourteen have given a hold rating, ten have assigned a buy rating and one has issued a strong buy rating to the stock. The stock currently has a consensus rating of “Hold” and an average price target of GBX 4,926.80 ($64.31).

Shares of AstraZeneca plc (LON:AZN) opened at 4990.24 on Monday. The firm’s market cap is GBX 63.13 billion. AstraZeneca plc has a 52 week low of GBX 3,680.00 and a 52 week high of GBX 5,505.00. The firm has a 50-day moving average price of GBX 5,015.00 and a 200-day moving average price of GBX 4,398.79.

The firm also recently announced a dividend, which was paid on Monday, September 12th. Investors of record on Thursday, August 11th were given a dividend of GBX 68.70 ($0.90) per share. This represents a dividend yield of 1.37%. The ex-dividend date was Thursday, August 11th.

AstraZeneca plc Company Profile

AstraZeneca PLC (AstraZeneca) is a biopharmaceutical company. The Company focuses on the discovery, development and commercialization of prescription medicines, primarily for the treatment of diseases in various therapy areas, including respiratory, inflammation, autoimmune disease (RIA), cardiovascular and metabolic disease (CVMD) and oncology, as well as in infection, neuroscience and gastrointestinal areas.

Receive News & Stock Ratings for AstraZeneca plc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for AstraZeneca plc and related stocks with our FREE daily email newsletter.